BRIEF—Novo analyses show positive kidney outcomes

Novo Nordisk has revealed new analyses from the SUSTAIN 6 and LEADER trials, comparing Ozempic (semaglutide) and Victoza (liraglutide) with placebo on renal outcomes, in people with type 2 diabetes at high CV risk.

There were significant beneficial effects on kidney function and renal outcomes, with fewer people showing a persistent eGFR reduction, and a significantly slower annual loss of kidney function.

Chief scientific officer Mads Krogsgaard Thomsen said: “Cardiovascular disease, chronic kidney disease and diabetes are inextricably linked and there's a significant unmet need for new and effective treatment options in people with type 2 diabetes.”

“The positive effect on renal outcomes seen in SUSTAIN 6 and LEADER suggest that Ozempic and Victoza slow down the progression of diabetic kidney disease.”

“To dig deeper into this, we are initiating the first-ever dedicated renal outcomes trial, called FLOW, with a GLP-1 receptor agonist in diabetic kidney disease.”